PHAT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
84.7M
+14.1%
74.3M
+27.4%
58.3M
+1.2%
57.6M
+16.3%
49.5M
Cost of Revenue
18.4M
+21.7%
15.1M
+25.8%
12.0M
+56.9%
7.6M
+23.6%
6.2M
Gross Profit
66.4M
+12.1%
59.2M
+27.8%
46.3M
-7.3%
49.9M
+15.3%
43.3M
Operating Expenses
66.4M
+5.2%
63.1M
+2.2%
61.8M
+10.6%
55.9M
-4.6%
58.6M
R&D
8.7M
+11.9%
7.8M
+0.5%
7.8M
+3.7%
7.5M
+6.6%
7.0M
SG&A
57.7M
+4.3%
55.3M
+2.4%
54.0M
+11.7%
48.4M
-6.2%
51.6M
Operating Income
-85000
+97.9%
-3965000
+74.4%
-15477000
-161.1%
-5928000
+61.2%
-15271000
EBITDA
35.0K
+100.9%
-3851000
+74.9%
-15367000
-164.9%
-5800000
+61.6%
-15115000
Net Income
-13897000
+21.0%
-17582000
+42.1%
-30369000
-43.6%
-21148000
+29.4%
-29973000
EPS (Basic)
$-0.16
+23.8%
$-0.21
+43.2%
$-0.37
-27.6%
$-0.29
+29.3%
$-0.41
EPS (Diluted)
$-0.16
+23.8%
$-0.21
+43.2%
$-0.37
-27.6%
$-0.29
+29.3%
$-0.41
Shares (Diluted)
84.9M
+1.4%
83.7M
+2.1%
82.1M
+11.1%
73.8M
+0.6%
73.4M
Phathom Pharmaceuticals (PHAT) — Financials